IXICO Dirección

Dirección controles de criterios 2/4

El CEO de IXICO es Bram Goorden, nombrado en Aug 2024, tiene una permanencia de menos de un año. posee directamente un 0.57% de las acciones de la empresa, con un valor de €78.78K. La antigüedad media del equipo directivo y de la junta directiva es de 7.3 años y 4 años, respectivamente.

Información clave

Bram Goorden

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.6%
Permanencia media de la dirección	7.3yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Bram Goorden (50 yo)

less than a year

Permanencia

Mr. Bram Goorden, M.Sc., serves as Chief Executive Officer of IXICO plc since August 19, 2024. He served as Chief Operating Officer and Senior Vice President at SOPHiA GENETICS SA since August 2020 until 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Grant Nash	CFO, Company Secretary & Executive Director	5.6yrs	UK£216.00k	0.55% € 75.6k
Bram Goorden	Chief Executive Officer	less than a year	sin datos	0.57% € 78.8k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	20.8yrs	sin datos	sin datos
Derek Lionel Hill	Co-Founder and President of Regulatory Science & External Relations	7.3yrs	UK£387.01k	sin datos
David Hawkes	Co-Founder & Member of Scientific Advisory Board	20.8yrs	sin datos	sin datos
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	20.8yrs	sin datos	sin datos
Mark Austin	Director of Technology	no data	sin datos	sin datos
Robin Wolz	Chief Scientific Officer	no data	sin datos	sin datos
Hannah Esfahanian	HR Manager	no data	sin datos	sin datos
John Hall	Senior Vice President of Business Development	8.5yrs	sin datos	sin datos
Lammert Albers	Chief Business Officer	5.1yrs	sin datos	sin datos
Alison Howie	Chief Product Officer	6.4yrs	sin datos	sin datos

7.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PYPB es experimentado (7.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Grant Nash	CFO, Company Secretary & Executive Director	5.3yrs	UK£216.00k	0.55% € 75.6k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
David Hawkes	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Dipti Amin	Independent Non-Executive Director	1.1yrs	sin datos	0.11% € 15.8k
Mark Warne	Independent Non-Executive Chair	8.2yrs	UK£31.00k	0.078% € 10.8k
Katherine Rogers	Senior Independent Non-Executive Director	2.8yrs	UK£31.00k	0.057% € 7.9k

4.0yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de PYPB se considera experimentada (4 años de antigüedad promedio).

IXICO Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

IXICO plc, Annual General Meeting, Jan 25, 2024

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

IXICO plc, Annual General Meeting, Jan 27, 2023

Recent updates

IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024

New major risk - Share price stability

New major risk - Shareholder dilution

Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

New major risk - Revenue and earnings growth

IXICO plc to Report First Half, 2024 Results on May 21, 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

Full year 2023 earnings released: UK£0.024 loss per share (vs UK£0.021 profit in FY 2022)

IXICO plc, Annual General Meeting, Jan 25, 2024

IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023

New major risk - Market cap size

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

New major risk - Revenue and earnings growth

IXICO plc Provides Earnings Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022)

IXICO plc to Report First Half, 2023 Results on May 23, 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

Full year 2022 earnings released: EPS: UK£0.021 (vs UK£0.033 in FY 2021)

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Financial Year 2023

First half 2022 earnings released

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022

IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020)

Investor sentiment improved over the past week

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited

Investor sentiment improved over the past week

IXICO plc Announces Collaboration with Microsoft

Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial

IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc

New 90-day low: €0.98

IXICO Secures New Contract for £3.4 Million

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS UK£0.02

Revenue beats expectations

IXICO plc, Annual General Meeting, Jan 21, 2021

IXICO plc Announces £1.9 Million New Study Award

Market bids up stock over the past week

New 90-day high: €1.26

Market bids up stock over the past week

IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020

Market bids up stock over the past week

New 90-day high: €1.22

Market bids up stock over the past week

IXICO plc and NYU Langone Health Signs Agreement

IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease

Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance

Global Alzheimer's Platform Foundation Selects IXICO plc for Innovative Bio-Hermes Trial

New 90-day high - €0.94

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad